Since Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and ArQule Inc. (NASDAQ:ARQL) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation of both companies.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Alexion Pharmaceuticals Inc.||4.13B||7.37||77.60M||0.08||1767.27|
Table 1 highlights Alexion Pharmaceuticals Inc. and ArQule Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 represents Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and ArQule Inc. (NASDAQ:ARQL)’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Alexion Pharmaceuticals Inc.||1.88%||0.9%||0.6%|
Risk and Volatility
A 1.57 beta indicates that Alexion Pharmaceuticals Inc. is 57.00% more volatile compared to Standard & Poor’s 500. In other hand, ArQule Inc. has beta of 2.12 which is 112.00% more volatile than Standard & Poor’s 500.
Alexion Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 2.9 and 2.5 respectively. The Current Ratio and Quick Ratio of its competitor ArQule Inc. are 9.6 and 9.6 respectively. ArQule Inc. therefore has a better chance of paying off short and long-term obligations compared to Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc. and ArQule Inc. Ratings and Recommendations are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Alexion Pharmaceuticals Inc.||0||1||5||2.83|
Alexion Pharmaceuticals Inc. has a consensus price target of $167.67, and a 23.58% upside potential. Competitively ArQule Inc. has a consensus price target of $7.69, with potential upside of 23.83%. The information presented earlier suggests that ArQule Inc. looks more robust than Alexion Pharmaceuticals Inc. as far as analyst view.
Institutional and Insider Ownership
The shares of both Alexion Pharmaceuticals Inc. and ArQule Inc. are owned by institutional investors at 96.9% and 81% respectively. Alexion Pharmaceuticals Inc.’s share owned by insiders are 0.1%. Competitively, 1.26% are ArQule Inc.’s share owned by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Alexion Pharmaceuticals Inc.||2.19%||10.67%||10.78%||10.81%||18.22%||39.77%|
For the past year Alexion Pharmaceuticals Inc. has stronger performance than ArQule Inc.
Alexion Pharmaceuticals Inc. beats on 9 of the 13 factors ArQule Inc.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death. Its pre-clinical development program also includes ARQ 531, an inhibitor of BrutonÂ’s tyrosine kinase. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; and collaborative research and development agreement with Beryllium Development Corp. Arqule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.